X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). It is being evaluated for the treatment of gout flares.
Lead Product(s): Colchicine,Ropivacaine Hydrochloride
Therapeutic Area: Rheumatology Product Name: PKM-01
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
PRF-110 (ropivacaine) is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: PRF-110
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lotus Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
CPL-01 is an extended-release injectable formulation of Naropin® (ropivacaine hydrochloride), which is a member of the amino amide class of local anesthetics indicated for the production of local or regional anesthesia for surgery and acute pain management.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: CPL-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
In the dose currently planned as the to-be marketed dose, 14 subjects who received CPL-01 showed a mean AUC through 72 hours of wWOCF adjusted NRS-A of 286.8, showing a trend towards significance against the 13 subjects who received placebo.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: CPL-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
PRF-110 is based on the local anesthetic ropivacaine, targeting post-operative pain relief market. PRF-110 is an oil-based, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: PRF-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
The company's lead candidate and first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. Company plans to initiate two Phase 3 trials for PRF-110 soon after the closing of this offering.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: PRF-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maxim Group LLC
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2020
Details:
Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours. TLC590 a non-opioid, proprietary BioSeizer sustained release formulation of ropivacaine.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: TLC590
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2020
Details:
The randomized, double-blind, comparator- and placebo-controlled study will evaluate the analgesic efficacy and safety of TLC590 for postsurgical pain management in patients following bunionectomy.
Lead Product(s): Ropivacaine Hydrochloride
Therapeutic Area: Neurology Product Name: TLC590
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
